Anika Therapeutics
(NASDAQ) ANIK
Anika Therapeutics Financials at a Glance
Market Cap
$204.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$116.26M
Net Income (TTM)
-$11.06M
EPS (TTM)
-$0.79
P/E Ratio
-19.40
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Price
$15.97
Volume
58,715.017
Open
$15.30
Price
$15.97
Volume
58,715.017
Open
$15.30
Previous Close
$16.03
Daily Range
$15.17 - $16.28
52-Week Range
$7.87 - $16.28
Estimated Earnings Date
Jul 29, 2026
Dividend
$0.00
Beta (Volatility)
0.83 (Low)
Price
$15.97
Volume
58,715.017
Open
$15.30
Previous Close
$16.03
Daily Range
$15.17 - $16.28
52-Week Range
$7.87 - $16.28
Estimated Earnings Date
Jul 29, 2026
ANIK News
3 Biotech Stocks to Buy in May
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Anika Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
235
CEO
Stephen D. Griffin, MBA
Website
www.anika.comHeadquarters
Bedford, MA 01730, US
ANIK Financials
Key Financial Metrics (TTM)
Gross Margin
58.59%
Operating Margin
-10.54%
Net Income Margin
-9.52%
Return on Equity
-7.74%
Return on Capital
-6.51%
Return on Assets
-6.17%
Earnings Yield
-5.15%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$204.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
13.31M
Volume
58.72K
Avg. Volume
95.99K
Financials (TTM)
Gross Profit
$68.12M
Operating Income
-$12.25M
EBITDA
-$4.63M
Operating Cash Flow
$6.47M
Capital Expenditure
-$5.43M
Free Cash Flow
$1.04M
Cash & ST Invst.
$41.02M
Total Debt
$25.74M
Anika Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$29.61M
+13.2%
Gross Profit
$19.00M
+29.4%
Gross Margin
64.15%
N/A
Market Cap
$204.37MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$709.63K
N/A
Employees
288
N/A
Net Income
-$5.06M
-3.8%
EBITDA
-$3.41M
-49.9%
Quarterly Fundamentals
Total Cash
$41.02M
-23.1%
Total Debt
$25.74M
+1.2%
Accounts Receivable
$25.77M
+17.2%
Inventory
$22.84M
+7.0%
Long Term Debt
$23.79M
+1.0%
Short Term Debt
$1.94M
+3.6%
Return on Assets
-6.17%
N/A
Return on Invested Capital
-7.74%
N/A
Free Cash Flow
-$6.28M
-112.5%
Operating Cash Flow
-$4.85M
-3627.7%